Butterfly on yellow flowers for EicOsis home page

Developing a Safer Approach to Treat Pain and Inflammation

At EicOsis we are advancing novel, safe and effective oral treatments for patients suffering from pain and inflammation.

Discover More

Pain and Inflammation

Understand the unmet needs of those suffering from pain or inflammatory conditions, and how EicOsis is working to make a difference in their lives.

Our Approach

Learn how our novel technology, targeting the soluble Epoxide Hydrolase, can help us develop new safe and effective oral analgesics and anti-inflammatories.

Media & Investors

Spread the news on EicOsis’s progresses and learn about our commitment to to improve the lives of those suffering from pain and inflammation.

Addressing the Urgent Need for Better Chronic Pain Drugs and Fighting the Opioid Crisis

 

Chronic pain affects 100 million Americans and causes a substantial physical and emotional impact on their lives. Current treatments for pain are insufficient, and patients are often prescribed opioids. Increased prescription of opioids has led to a widespread public health emergency, the US Opioid Crisis. There is an unmet need for safe, non-addictive and effective pain medications that can help pain patients and fight the US Opioid Crisis.

At EicOsis we are developing a new approach to treat pain and inflammation by inhibiting the soluble Epoxide Hydrolase (sEH), a key regulatory enzyme. Inhibiting sEH increases the levels of naturally occurring anti-inflammatory and pain-relieving compounds. Our first drug candidate is currently undergoing Phase 1 human clinical trials. Learn more about EicOsis Human Health.

Hands clasping after treatment for pain

Latest News: EicOsis Continues Advancing EC5026 through Phase 1 Clinical Trials

June 2021: EicOsis has initiated a Phase 1 fed-fasted, single dose clinical trial of EC5026, our oral drug candidate for the treatment of pain. This trial comes after a successful single-ascending dose clinical trial with no drug-related adverse events in healthy volunteers.

Learn More

EicOsis Has Been Awarded over 20 Million in Competitive Grants and Funding

EicOsis is advancing its first drug candidate to human clinical trials with the support of funding from federal grants and angel investors.

February, 2021 – Veterans Affairs investigator recibes Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award from the Department of Defense to conduct clinical trial of EC5026 for neuropathic pain

October, 2019 – EicOsis receives SBIR grant award from NCI/NIH

October, 2019 – EicOsis receives $15 M from NIDA/NIH as part of the HEAL Initiative

March, 2019 – EicOsis raises funding for Phase 1 clinical development from Open Philanthropy

January, 2019 – EicOsis receives $4 M from NIH Blueprint for Neuroscience Research to advance oral analgesic to Phase 1 clinical trials for neuropathic pain

Learn more about our funding sources.